These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Reactivation of retinopathy of prematurity after bevacizumab injection. Hu J; Blair MP; Shapiro MJ; Lichtenstein SJ; Galasso JM; Kapur R Arch Ophthalmol; 2012 Aug; 130(8):1000-6. PubMed ID: 22491394 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction. Ramasubramanian A; Shields CL Br J Ophthalmol; 2012 Mar; 96(3):356-9. PubMed ID: 21653215 [TBL] [Abstract][Full Text] [Related]
18. Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab. Barry GP; Tauber KA; Fisher M; Greenberg S; Zobal-Ratner J; Binenbaum G J AAPOS; 2019 Oct; 23(5):260.e1-260.e4. PubMed ID: 31513902 [TBL] [Abstract][Full Text] [Related]
19. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor. Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G; Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554 [TBL] [Abstract][Full Text] [Related]
20. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA; JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]